A larger screening of patient’s samples, part of the American Association for Cancer Research “GENIE” initiative [108], has recently identified occasional mutations of NSD2 in small percentages of hematologic cancers such as non-Hodgkin lymphomas (NSD2 is altered in 2.86% of the patients), Hodgkin lymphoma (1.79%), diffuse large B-cell lymphoma (2.58%), or chronic lymphocytic leukemia/small lymphocytic lymphoma (0.53%) [108]. Here, NSD2 is linked to diffuse large B-cell lymphoma.